A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis
2019 ◽
Vol 31
(1)
◽
pp. 85-87
◽
Keyword(s):
This study presents a case report of a 31-year-old gay man who acquired human immunodeficiency virus while using daily emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP). He had an M184V nucleoside reverse-transcriptase inhibitor mutation at diagnosis. Either he acquired a pre-existing M184V mutation or he acquired a wild-type virus but then suboptimal use of FTC/TDF led to the development of resistance. For PrEP to be safely managed and seroconvertors to be identified quickly, PrEP should be commissioned by the NHS and managed within sexual health clinics. Notwithstanding the current provision of PrEP, those accessing it must be reminded about the importance of regular testing and optimal adherence.
2007 ◽
Vol 51
(8)
◽
pp. 2701-2708
◽
1996 ◽
Vol 40
(11)
◽
pp. 2664-2668
◽
1995 ◽
Vol 171
(5)
◽
pp. 1159-1165
◽
1987 ◽
Vol 31
(10)
◽
pp. 1524-1528
◽
2004 ◽
Vol 48
(4)
◽
pp. 1413-1415
◽
1994 ◽
Vol 47
(11)
◽
pp. 2017-2028
◽
2007 ◽
Vol 156
(1)
◽
pp. 163-164
◽